Comparative Pharmacology
Head-to-head clinical analysis: PULMICORT FLEXHALER versus PULMICORT RESPULES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PULMICORT FLEXHALER versus PULMICORT RESPULES.
PULMICORT FLEXHALER vs PULMICORT RESPULES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Budesonide is a corticosteroid with potent anti-inflammatory effects. It inhibits multiple inflammatory cell types and mediators such as cytokines, chemokines, and adhesion molecules, reducing airway hyperresponsiveness and inflammation.
Glucocorticoid receptor agonist; anti-inflammatory; decreases cytokine production, inhibits inflammatory cell migration, and reduces airway hyperresponsiveness.
Inhalation: 1-2 inhalations (90-180 mcg) twice daily; maximum 720 mcg twice daily.
0.5 mg to 1 mg twice daily via nebulization; for maintenance or as replacement therapy, initiate at 0.25 mg twice daily and titrate to clinical response.
None Documented
None Documented
Terminal half-life: 2.0-3.5 hours (mean 2.5 h) in adults after inhalation. Clinically, duration of effect may persist beyond pharmacokinetic half-life due to receptor binding.
Terminal half-life approximately 2-3 hours in children and adults; slightly prolonged in hepatic impairment. Clinical context: supports twice-daily dosing in asthma.
Renal: ~60% as metabolites, fecal: ~40% as metabolites. Less than 10% unchanged in urine.
Renal: negligible (<5% as unchanged drug). Biliary/fecal: major route, approximately 60-70% as metabolites. Total clearance: 0.5-1.0 L/h.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid